查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153373

2026-2034年全球個人化癌症醫療市場規模、佔有率、趨勢和成長分析報告

Global Personalized Cancer Medicine Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 168 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球個人化癌症治療市場預計將從2025年的3,911.4億美元成長至2034年的8,144億美元，2026年至2034年的複合年成長率（CAGR）為8.49%。這一市場擴張的驅動力在於腫瘤學領域日益重視根據個別腫瘤和每位患者的生物學特徵制定個人化治療策略。個人化癌症治療利用基因突變、分子生物標記和其他疾病特徵等資訊來幫助選擇合適的治療方案。人們越來越認知到，即使是同一種癌症，患者對治療的反應也可能不同，這推動了個人化治療方法的應用。腫瘤譜分析和標靶藥物研發的進步使得更精準的治療策略成為可能。醫療服務提供者擴大利用分子資訊來識別潛在的治療方案，並提高治療方案與疾病特徵的匹配度。

基因測序技術的進步、標靶治療的日益普及以及免疫腫瘤學研究的不斷拓展，正在推動市場成長。製藥公司正在開發針對特定分子路徑的療法，而診斷實驗室也不斷改進生物標記檢測的可及性。臨床試驗擴大採用分子水平的標準來識別可能受益於臨床實驗藥物的患者。生技公司、研究機構和醫療服務提供者之間的合作也正在加速個人化治療方案的發展。此外，生物資訊學和臨床數據分析的進步也使研究人員更容易解讀複雜的生物資訊並發現新的治療機會。

該市場的未來前景取決於生物標記發現、療法研發以及分子檢測融入常規癌症診療的持續進展。在某些臨床情況下，液態生物檢體技術可望輔助疾病監測並識別新的抗藥性機制。人工智慧 (AI) 可以改善基因組和臨床數據的分析，幫助研究人員識別與治療反應相關的模式。聯合治療和個人化免疫療法也有望拓展治療選擇。然而，檢測和治療高成本、保險報銷有限、腫瘤異質性以及獲得專科醫療服務的機會不均等問題仍然是重大挑戰。解決這些挑戰對於更廣泛地應用這些技術至關重要。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球個人化癌症治療市場：依產品分類

  • 市場分析、洞察與預測
  • 個性化醫療診斷
  • 個人化醫療藥物

第5章：全球個人化癌症治療市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院和診所
  • 其他

第6章：全球個人化癌症治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Roche
    • Thermo Fisher Scientific
    • Illumina
    • Foundation Medicine
    • Guardant Health
    • Exact Sciences
    • Tempus AI
    • Caris Life Sciences
    • Natera
    • NeoGenomics
    • QIAGEN
    • AstraZeneca
    • Novartis
    • Pfizer
    • Bristol Myers Squibb
    • Merck & Co
    • Johnson & Johnson
    • Amgen
    • Gilead Sciences
    • BioNTech
簡介目錄
Product Code: VMR112111855

The global personalized cancer medicine market size is expected to reach USD 814.40 Billion in 2034 from USD 391.14 Billion in 2025, growing at a CAGR of 8.49% during 2026-2034.This market is growing as oncology increasingly focuses on tailoring treatment decisions to the biological characteristics of individual tumors and patients. Personalized cancer medicine uses information such as genetic alterations, molecular biomarkers, and other disease characteristics to guide the selection of suitable therapies. Growing recognition that patients with the same cancer type may respond differently to treatment is encouraging the adoption of individualized approaches. Advances in tumor profiling and targeted drug development are supporting more precise treatment strategies. Healthcare providers are increasingly using molecular information to identify potential treatment options and improve the alignment between therapies and disease characteristics.

Market growth is driven by progress in genomic sequencing, increasing availability of targeted therapies, and expanding research into immuno-oncology. Pharmaceutical companies are developing treatments directed at specific molecular pathways, while diagnostic laboratories are improving access to biomarker testing. Clinical trials increasingly incorporate molecular criteria to identify patients who may benefit from investigational therapies. Collaborations among biotechnology companies, research institutions, and healthcare providers are also accelerating the development of personalized treatment approaches. In addition, improvements in bioinformatics and clinical data analysis are helping researchers interpret complex biological information and identify new therapeutic opportunities.

The future prospects of this market will depend on continued advances in biomarker discovery, treatment development, and the integration of molecular testing into routine cancer care. Liquid biopsy technologies may support disease monitoring and the identification of emerging resistance mechanisms in selected clinical settings. Artificial intelligence could improve the analysis of genomic and clinical data, helping researchers identify patterns associated with treatment response. Combination therapies and personalized immunotherapy approaches may also expand treatment options. However, high testing and treatment costs, reimbursement limitations, tumor heterogeneity, and unequal access to specialized care remain significant challenges. Addressing these issues will be important for broader adoption.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Product

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics

By End User

  • Hospitals and clinics
  • Others

COMPANIES PROFILED

  • Roche, Thermo Fisher Scientific, Illumina, Foundation Medicine, Guardant Health, Exact Sciences, Tempus AI, Caris Life Sciences, Natera, NeoGenomics, QIAGEN, AstraZeneca, Novartis, Pfizer, Bristol Myers Squibb, Merck & Co., Johnson & Johnson, Amgen, Gilead Sciences, BioNTech

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PERSONALIZED CANCER MEDICINE MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Product
  • 4.2. Personalized Medicine Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Personalized Medicine Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PERSONALIZED CANCER MEDICINE MARKET: BY END USER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End User
  • 5.2. Hospitals and clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PERSONALIZED CANCER MEDICINE MARKET: BY REGION 2022-2034 (USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Product
    • 6.2.2 By End User
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Product
    • 6.3.2 By End User
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Spain
    • 6.3.8 Russia
    • 6.3.9 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Product
    • 6.4.2 By End User
    • 6.4.3 China
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 India
    • 6.4.7 Australia
    • 6.4.8 South East Asia
    • 6.4.9 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Product
    • 6.5.2 By End User
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Product
    • 6.6.2 By End User
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL PERSONALIZED CANCER MEDICINE INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Roche
    • 8.2.2 Thermo Fisher Scientific
    • 8.2.3 Illumina
    • 8.2.4 Foundation Medicine
    • 8.2.5 Guardant Health
    • 8.2.6 Exact Sciences
    • 8.2.7 Tempus AI
    • 8.2.8 Caris Life Sciences
    • 8.2.9 Natera
    • 8.2.10 NeoGenomics
    • 8.2.11 QIAGEN
    • 8.2.12 AstraZeneca
    • 8.2.13 Novartis
    • 8.2.14 Pfizer
    • 8.2.15 Bristol Myers Squibb
    • 8.2.16 Merck & Co
    • 8.2.17 Johnson & Johnson
    • 8.2.18 Amgen
    • 8.2.19 Gilead Sciences
    • 8.2.20 BioNTech